Immune-based Therapies
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
Tumori 2024 February 19 [Link] Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso Abstract Background:…
Read MoreMononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma
Frontiers in Neurology 2024 January 25 [Link] Antonio Farina, Manon Escalere, Matthias Dion, Martin Moussy, Antoine Pegat, Macarena Villagrán-García, Perrine Devic, Anaïde Lamiral, Antoine Seyve, Karine Aure, Adrien Wang, Lucas Gorza, Nathalie Streichenberger, Thierry Maisonobe, Jerome Honnorat, Cristina Birzu, Dimitri Psimaras, David Weisenburger-Lile, Bastien Joubert Abstract Introduction: Mononeuritis multiplex is frequently related to vasculitic neuropathy…
Read MoreImmunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Frontiers in Immunology 2024 January 8 [Link] Luana Calabrò, Giuseppe Bronte, Federica Grosso, Luigi Cerbone, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Lucio Crinò, Michele Maio Abstract Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the…
Read MoreAntipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells
Cancer Science 2023 December 26 [Link] Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka Abstract Combination immunotherapy with multiple immune checkpoint inhibitors (ICIs) has been approved for various types of malignancies, including malignant…
Read MoreNiraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial
Clinical Cancer Research 2023 December 18 [Link] Francesco Passiglia, Luisella Righi, Paolo Bironzo, Angela Listì, Giovanni Farinea, Enrica Capelletto, Silvia Novello, Alessandra Merlini, Giorgio V Scagliotti Abstract Introduction: Treatment of homologous recombination repair deficient (HRD)-tumours with PARP inhibitors has the potential to further increase tumour immunogenicity, suggesting a synergistic effect with immunotherapy. Here we present…
Read MoreAnti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model
Frontiers in Immunology 2023 November 23 [Link] Ka Sin Lui, Zuodong Ye, Hoi Ching Chan, Yoshimasa Tanaka, Allen Ka Loon Cheung Abstract Introduction: Mesothelioma is an aggressive tumor in the pleural cavity that is difficult to treat. Diagnosis is usually late with minimal treatment options available for the patients and with unfavorable outcomes. However, recent…
Read MoreMalignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors
Targeted Oncology 2023 December 8 [Link] Serafina Martella, Marco Maria Aiello, Valentina Bertaglia, Riccardo Cau, Nerina Denaro, Andrea Cadoni, Silvia Novello, Mario Scartozzi, Giuseppe Novello, Hector Josè Soto Parra, Luca Saba, Cinzia Solinas, Michele Porcu Abstract Malignant pleural mesothelioma (MPM) is a rare and challenging cancer associated with asbestos fiber exposure, which offers limited treatment…
Read MoreCombined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
Cancer Research Communications 2024 January 3 [Link] Jitendra Badhai, Nick Landman, Gaurav Kumar Pandey, Ji-Ying Song, Danielle Hulsman, Oscar Krijgsman, Gayathri Chandrasekaran, Anton Berns, Maarten van Lohuizen Abstract Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using…
Read MoreSalvage pleurectomy/decortication following immunotherapy for malignant pleural mesothelioma
Interdisciplinary Cardiovascular and Thoracic Surgery 2023 November 15 [Link] Masaru Takenaka, Koji Kuroda, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Fumihiro Tanaka Abstract Salvage surgery following immunotherapy is a promising treatment option for advanced malignant tumour. However, only a few cases of salvage surgery for malignant pleural mesothelioma (MPM) have been reported.…
Read MoreDevelopment of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Nature Communications 2023 November 3 [Link] Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, Mikko Mäyränpää, Jukka Partanen, Satu Koskela, Jarno Honkanen, Jussi Halonen, Lukasz Kuryk, Maria Rescigno, Mikaela Grönholm, Rui M Branca, Janne Lehtiö, Vincenzo Cerullo…
Read More